A multi-strategy antimicrobial discovery approach reveals new ways to treat Chlamydia
PLOS Biology · 2025
DOI: 10.1371/journal.pbio.3003123 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Biology, 2025. Verfasst von Magnus Ölander und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, Umeå University, Umeå, Sweden. Hauptthemen laut MEDLINE: Chlamydia Infections, Anti-Bacterial Agents, Drug Discovery, Chlamydia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Vetenskapsrådet, Kempestiftelserna.
Abstract (Originalsprache)
While the excessive use of broad-spectrum antibiotics is a major driver of the global antibiotic resistance crisis, more selective therapies remain unavailable for the majority of bacterial pathogens. This includes the obligate intracellular bacterial pathogens of the genus Chlamydia , which cause millions of urogenital, ocular, and respiratory infections each year. Conducting a comprehensive search of the chemical space for novel antichlamydial activities, we identified over 60 compounds that are chemically diverse, structurally distinct from known antibiotics, non-toxic to human cells, and highly potent in preventing the growth of Chlamydia trachomatis in cell cultures. Some blocked C. trachomatis development reversibly, while others eradicated both established and persistent infections in a bactericidal manner. The top molecules displayed compelling selectivity, yet broad activity against diverse Chlamydia strains and species, including both urogenital and ocular serovars of C . trachomatis , as well as Chlamydia muridarum and Chlamydia caviae . Some compounds also displayed synergies with clinically used antibiotics. Critically, we found the most potent antichlamydial compound to inhibit fatty acid biosynthesis via covalent binding to the active site of Chlamydia FabH, identifying a new mechanism of FabH inhibition and highlighting a possible way to selectively treat Chlamydia infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology, Umeå University, Umeå, Sweden.
- The Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå University, Umeå, Sweden.
- Umeå Centre for Microbial Research (UCMR), Umeå University, Umeå, Sweden.
- Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan, United States of America.
- Department of Chemistry, Umeå University, Umeå, Sweden.
ORCID-Profile: Barbara S Sixt
Förderung
- NIGMS NIH HHS
- Vetenskapsrådet
- Kempestiftelserna
- National Institutes of Health
Zitieren
APA
Ölander, M., Rea Vázquez, D., Meier, K., Singh, A., Silva de Sousa, A., Puértolas-Balint, F., Milivojevic, M., Mooij, L., Fredlund, J., Calpe Bosch, E., Rayón Díaz, M., Lundgren, M., van der Wal, K., Zhu, S., Mateus, A., Schroeder, B. O., Lohman, J. R., & Sixt, B. S. (2025). A multi-strategy antimicrobial discovery approach reveals new ways to treat Chlamydia. PLOS Biology. https://doi.org/10.1371/journal.pbio.3003123
Vancouver
Ölander M, Rea Vázquez D, Meier K, Singh A, Silva de Sousa A, Puértolas-Balint F, et al. A multi-strategy antimicrobial discovery approach reveals new ways to treat Chlamydia. PLOS Biology. 2025. doi:10.1371/journal.pbio.3003123
BibTeX
@article{lander2025,
author = {Ölander, Magnus and Rea Vázquez, Daniel and Meier, Karsten and Singh, Aakriti and Silva de Sousa, Amanda and Puértolas-Balint, Fabiola and Milivojevic, Milica and Mooij, Lieke and Fredlund, Johanna and Calpe Bosch, Eduard and Rayón Díaz, María and Lundgren, Moa and van der Wal, Karin and Zhu, Shaochun and Mateus, André and Schroeder, Bjoern O and Lohman, Jeremy R and Sixt, Barbara S},
title = {A multi-strategy antimicrobial discovery approach reveals new ways to treat Chlamydia},
journal = {PLOS Biology},
year = {2025},
doi = {10.1371/journal.pbio.3003123}
}
EUVIMED